Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in FranceReport as inadecuate

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France - Download this document for free, or read online. Document in PDF available to download.

Graefe-s Archive for Clinical and Experimental Ophthalmology

pp 1–10

First Online: 10 May 2017Received: 21 April 2016Revised: 13 March 2017Accepted: 24 April 2017DOI: 10.1007-s00417-017-3685-y

Cite this article as: Mimoun, G., Ebran, JM., Grenet, T. et al. Graefes Arch Clin Exp Ophthalmol 2017. doi:10.1007-s00417-017-3685-y


PurposeTo evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization CNV secondary to pseudoxanthoma elasticum PXE in a real-world setting.

MethodsA descriptive, observational, multicenter study in a retrospective and prospective cohort was conducted in France that included patients who had received at least one injection of ranibizumab 0.5 mg during the period October 2011 to October 2014, for CNV secondary to PXE. Eligible patients were identified by review of medical records or during routine consultations. The main objectives were to describe patient characteristics, assess changes in best-corrected visual acuity VA, Early Treatment Diabetic Retinopathy Study ETDRS letters over time, the number and reasons for ranibizumab treatment and overall safety.

ResultsOf the 72 enrolled patients 98 eyes from 23 centers, 39 54.2% were male and mean ±standard deviation SD age was 59.6 ±8.3 years. The mean VA was 64.6 letters at the first ranibizumab injection, which was maintained at the 1-year follow-up 64.7 letters. Thereafter, the mean VA was stable until the 4-year follow-up. At 4 years, the proportion of eyes with VA gain of ≥15 letters was 3-19 15.8% and stable VA change between −15 and +15 letters was 10-19 52.6%. Mean ±SD annual number of ranibizumab injections was 4.1 ±4.0, lower in the second versus first year. The most common reason for ranibizumab treatment was progression of neovascular activity 42.9%. No deaths or new safety findings were reported.

ConclusionsIn patients with CNV secondary to PXE, ranibizumab 0.5 mg resulted in stable VA over 4 years with a limited number of injections. Safety findings were consistent with the established safety profile of ranibizumab.

KeywordsAngioid streaks Choroidal neovascularization Observational Pseudoxanthoma elasticum Ranibizumab 

Author: Gérard Mimoun - Jean-Marc Ebran - Typhaine Grenet - Alain Donati - Salomon-Yves Cohen - Anne Ponthieux

Source: https://link.springer.com/

Related documents